Biotech Holdings, Immunis Corp. deal

BIO purchased IMMC's 25 percent stake in BIO's DIAB II, an insulin-receptor sensitizer to treat Type II diabetes. IMMC, whose stake was in rights outside Oriental Asia, received 8.6 million shares of...